1.Periodontal Regeneration Using the Mixture of Human Tooth-ash and Plaster of Paris in Dogs.
Ha Ra GU ; Hyun Seon JANG ; Su wan KIM ; Joo Cheol PARK ; Byung Ock KIM
The Journal of the Korean Academy of Periodontology 2006;36(1):15-26
No abstract available.
Animals
;
Calcium Sulfate*
;
Dogs*
;
Humans*
;
Regeneration*
2.HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT.
Ha Ra GU ; Dong Yeop SHIN ; Hong Seok CHOI ; Chae Ho MOON ; Su Cheol PARK ; Hye Jin KANG
Blood Research 2015;50(1):51-53
Hepatitis B virus (HBV) reactivation has previously occurred in hepatitis B surface antigen-negative patients with malignant lymphoma who received rituximab-based combination chemotherapy. However, few reports have described cases of HBV reactivation in patients with multiple myeloma thus far. We report a case of HBV reactivation in a patient with multiple myeloma treated with chemotherapy, autologous hematopoietic stem cell transplantation, and maintenance steroid therapy. For the HBV reactivation, the patient was treated with the antiviral agent entecavir. The clinical symptoms and laboratory findings improved after 3 months. Further studies should target the identification of patients at high risk of HBV reactivation in multiple myeloma treated with autologous hematopoietic stem cell transplantation and steroid therapy for maintenance and establish viral prophylaxis strategies, especially in Korea, in which HBV infection is endemic.
Drug Therapy
;
Drug Therapy, Combination
;
Hematopoietic Stem Cell Transplantation
;
Hepatitis B
;
Hepatitis B virus
;
Humans
;
Korea
;
Lymphoma
;
Multiple Myeloma*
;
Prednisolone*
;
Transplantation
3.Corn silk extract improves benign prostatic hyperplasia in experimental rat model.
So Ra KIM ; Ae Wha HA ; Hyun Ji CHOI ; Sun Lim KIM ; Hyeon Jung KANG ; Myung Hwan KIM ; Woo Kyoung KIM
Nutrition Research and Practice 2017;11(5):373-380
BACKGROUND/OBJECTIVES: This study was conducted to investigate the effect of a corn silk extract on improving benign prostatic hyperplasia (BPH). MATERIALS/METHODS: The experimental animals, 6-week-old male Wistar rats, were divided into sham-operated control (Sham) and experimental groups. The experimental group, which underwent orchiectomy and received subcutaneous injection of 10 mg/kg of testosterone propionate to induce BPH, was divided into a Testo Only group that received only testosterone, a Testo+Fina group that received testosterone and 5 mg/kg finasteride, a Testo+CSE10 group that received testosterone and 10 mg/kg of corn silk extract, and a Testo+CSE100 group that received testosterone and 100 mg/kg of corn silk extract. Prostate weight and concentrations of dihydrotestosterone (DHT), 5α-reductase 2 (5α-R2), and prostate specific antigen (PSA) in serum or prostate tissue were determined. The mRNA expressions of 5α-R2 and proliferating cell nuclear antigen (PCNA) in prostate tissue were also measured. RESULTS: Compared to the Sham group, prostate weight was significantly higher in the Testo Only group and decreased significantly in the Testo+Fina, Testo+CSE10, and Testo+CSE100 groups (P < 0.05), results that were consistent with those for serum DHT concentrations. The concentrations of 5α-R2 in serum and prostate as well as the mRNA expression of 5α-R2 in prostate were significantly lower in the Testo+Fina, Testo+CSE10, and Testo+CSE100 groups than that in the Testo Only group (P < 0.05). Similarly, the concentrations of PSA in serum and prostate were significantly lower in the Testo+Fina, Testo+CSE10, and Testo+CSE100 groups (P < 0.05) than in the Testo Only group. The mRNA expression of PCNA in prostate dose-independently decreased in the Testo+CSE-treated groups (P < 0.05). CONCLUSIONS: BPH was induced through injection of testosterone, and corn silk extract treatment improved BPH symptoms by inhibiting the mRNA expression of 5α-R2 and decreasing the amount of 5α-R2, DHT, and PSA in serum and prostate tissue.
Animals
;
Dihydrotestosterone
;
Finasteride
;
Humans
;
Injections, Subcutaneous
;
Male
;
Models, Animal*
;
Orchiectomy
;
Proliferating Cell Nuclear Antigen
;
Prostate
;
Prostate-Specific Antigen
;
Prostatic Hyperplasia*
;
Rats*
;
Rats, Wistar
;
RNA, Messenger
;
Silk*
;
Testosterone
;
Testosterone Propionate
;
Zea mays*
4.Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Ha Ra GU ; Su Cheol PARK ; Su Jin CHOI ; Jae Cheol LEE ; You Cheoul KIM ; Chul Ju HAN ; Jin KIM ; Ki Young YANG ; Yeon Joo KIM ; Geum Youb NOH ; So Hyeon NO ; Jae Hoon JEONG
Clinical and Molecular Hepatology 2015;21(1):49-59
BACKGROUND/AIMS: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells. METHODS: Several different human HCC cell lines were used to test the growth-inhibiting effects and cell toxicity of silibinin both alone and in combination with either gefitinib or sorafenib. The cell viability and growth inhibition were assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, trypan blue staining, and a colony-forming assay. Furthermore, changes in epidermal growth factor receptor (EGFR)-related signals were evaluated by Western blot analysis. RESULTS: Gefitinib, sorafenib, and silibinin individually exhibited dose-dependent antiproliferative effects on HCC cells. Combined treatment with silibinin enhanced the gefitinib-induced growth-inhibiting effects in some HCC cell lines. The combination effect of gefitinib and silibinin was synergistic in the SNU761 cell line, but was only additive in the Huh-BAT cell line. The combination effect may be attributable to inhibition of EGFR-dependent Akt signaling. Enhanced growth-inhibiting effects were also observed in HCC cells treated with a combination of sorafenib and silibinin. CONCLUSIONS: Combined treatment with silibinin enhanced the growth-inhibiting effects of both gefitinib and sorafenib. Therefore, the combination of silibinin with either sorafenib or gefitinib could be a useful treatment approach for HCC in the future.
Antineoplastic Agents/*pharmacology
;
Carcinoma, Hepatocellular/metabolism/pathology
;
Cell Line, Tumor
;
Cell Proliferation/*drug effects
;
Cell Survival/drug effects
;
Down-Regulation/drug effects
;
Drug Screening Assays, Antitumor
;
Drug Synergism
;
Humans
;
Liver Neoplasms/metabolism/pathology
;
Niacinamide/*analogs & derivatives/pharmacology
;
Phenylurea Compounds/*pharmacology
;
Proto-Oncogene Proteins c-akt/metabolism
;
Quinazolines/*pharmacology
;
Receptor, Epidermal Growth Factor/metabolism
;
Signal Transduction/drug effects
;
Silymarin/*pharmacology
5.Erratum: Quatification of Flavonoid Contents in Chungsimyeonja-tang, a Multi-Herbal Decoction, and Its Protective Effect against Cisplatin-induced Nephrotoxicity.
Young Jung KIM ; Tae Won KIM ; Chang Seob SEO ; So Ra PARK ; Hyekyung HA ; Hyeun Kyoo SHIN ; Ju Young JUNG
Natural Product Sciences 2015;21(2):146-146
Correction for incorrect control groups (A, B, and C) at a Fig. 3. and Fig. 4. respectively. NPS 2014 20(4): 251-257.
6.A Multicenter Study to Identify the Respiratory Pathogens Associated with Exacerbation of Chronic Obstructive Pulmonary Disease in Korea
Hyun Woo LEE ; Yun Su SIM ; Ji Ye JUNG ; Hyewon SEO ; Jeong-Woong PARK ; Kyung Hoon MIN ; Jae Ha LEE ; Byung-Keun KIM ; Myung Goo LEE ; Yeon-Mok OH ; Seung Won RA ; Tae-Hyung KIM ; Yong il HWANG ; Chin Kook RHEE ; Hyonsoo JOO ; Eung Gu LEE ; Jin Hwa LEE ; Hye Yun PARK ; Woo Jin KIM ; Soo-Jung UM ; Joon Young CHOI ; Chang-Hoon LEE ; Tai Joon AN ; Yeonhee PARK ; Young-Soon YOON ; Joo Hun PARK ; Kwang Ha YOO ; Deog Kyeom KIM
Tuberculosis and Respiratory Diseases 2022;85(1):37-46
Background:
Although respiratory tract infection is one of the most important factors triggering acute exacerbation of chronic obstructive pulmonary disease (AE-COPD), limited data are available to suggest an epidemiologic pattern of microbiology in South Korea.
Methods:
A multicenter observational study was conducted between January 2015 and December 2018 across 28 hospitals in South Korea. Adult patients with moderate-to-severe acute exacerbations of COPD were eligible to participate in the present study. The participants underwent all conventional tests to identify etiology of microbial pathogenesis. The primary outcome was the percentage of different microbiological pathogens causing AE-COPD. A comparative microbiological analysis of the patients with overlapping asthma–COPD (ACO) and pure COPD was performed.
Results:
We included 1,186 patients with AE-COPD. Patients with pure COPD constituted 87.9% and those with ACO accounted for 12.1%. Nearly half of the patients used an inhaled corticosteroid-containing regimen and one-fifth used systemic corticosteroids. Respiratory pathogens were found in 55.3% of all such patients. Bacteria and viruses were detected in 33% and 33.2%, respectively. Bacterial and viral coinfections were found in 10.9%. The most frequently detected bacteria were Pseudomonas aeruginosa (9.8%), and the most frequently detected virus was influenza A (10.4%). Multiple bacterial infections were more likely to appear in ACO than in pure COPD (8.3% vs. 3.6%, p=0.016).
Conclusion
Distinct microbiological patterns were identified in patients with moderate-to-severe AE-COPD in South Korea. These findings may improve evidence-based management of patients with AE-COPD and represent the basis for further studies investigating infectious pathogens in patients with COPD.